Meeting
2019 ASCO Annual Meeting
Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma.
Authors
Mark R. Middleton
Churchill Hospital, Oxford, United Kingdom
Mark R. Middleton , Neil Matthew Steven , TR Jeffry Evans , Jeffrey R. Infante , Mario Sznol , Omid Hamid , Alexander Noor Shoushtari , Alan Anthoney , Avinash Gupta , Victoria K Woodcock , Rachael Easton , Philippa Gail Corrie
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01211262
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9530)
DOI
10.1200/JCO.2019.37.15_suppl.9530
Abstract #
9530
Poster Bd #
101
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.
First Author: Mark R. Middleton
Poster
2019 ASCO Annual Meeting
Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.
First Author: Mark R. Middleton
Poster
2020 ASCO Virtual Scientific Program
A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).
First Author: George R. Blumenschein, Jr.
Poster
2017 ASCO Annual Meeting
Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.
First Author: Takami Sato